
This study aimed to provide the clinical characteristics and outcomes of patients with both COVID-19 and diabetes mellitus receiving blood glucose-lowering therapies and COVID-19 symptomatic treatments. Most patients had an age range of 41-60 (76.1%), with more than half of the subjects (60%) obese. COVID-19 could affect the blood glucose level, suggesting the importance of antihyperglycemic therapies among patients with both COVID-19 and diabetes mellitus.
Like
Save
Share